RecruitingNCT05770687

SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Prospective, Multi-center Registry Study

Real World Observation of SGLT2 Inhibitors on Clinical Outcomes and Left Ventricular Remodeling in Type 2 Diabetic Patients with Acute Myocardial Infarction, a Prospective, Multi-center Registry Study

Sponsor

Kiyuk Chang

Enrollment

1,000 participants

Start Date

Aug 1, 2020

Study Type

OBSERVATIONAL

Conditions

Diabetes Mellitus, Type 2 Myocardial Infarction

Summary

Prospective trials performed on type 2 diabetes patients without established cardiovascular disease has shown that SGLT2 inhibitors reduce cardiovascular risk. No studies have yet examined the occurrence of cardiovascular disease in patients with acute myocardial infarction. The investigators designed the current study to evaluate the most ideal oral hypoglycemic agent in type 2 diabetes patients undergoing percutaneous coronary intervention for acute myocardial infarction. The investigators hypothesize that the use of SGLT-2 inhibitors will reduce cardiovascular events and modify left ventricular remodeling after myocardial infarctions.

Eligibility

Min Age: 19 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at whether a class of diabetes medications called SGLT2 inhibitors — drugs like dapagliflozin or empagliflozin — help the heart recover and work better after a heart attack. Researchers want to know if starting these pills around the time of a procedure to open blocked heart arteries (called a coronary stent or PCI) leads to better heart outcomes over time. **You may be eligible if...** - You had a heart attack and had a procedure to open a blocked artery (PCI/stent) - You have type 2 diabetes - You started an SGLT2 inhibitor within 1 month before or after the heart procedure **You may NOT be eligible if...** - You have type 1 diabetes - You use insulin or GLP-1 medications (like Ozempic or Victoza) - You were already taking an SGLT2 inhibitor before the heart attack - You are pregnant Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.